{"id":544622,"date":"2021-05-25T15:14:02","date_gmt":"2021-05-25T15:14:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=544622"},"modified":"2021-05-25T15:14:02","modified_gmt":"2021-05-25T15:14:02","slug":"osteosarcoma-market-size-epidemiology-treatment-therapies-and-companies-by-delveinsight-eleison-pharmaceuticals-aadi-bioscience-glaxosmithkline-bayer-eisai-limited-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/osteosarcoma-market-size-epidemiology-treatment-therapies-and-companies-by-delveinsight-eleison-pharmaceuticals-aadi-bioscience-glaxosmithkline-bayer-eisai-limited-and-others_544622.html","title":{"rendered":"Osteosarcoma Market Size, Epidemiology, Treatment, Therapies and Companies by DelveInsight | Eleison Pharmaceuticals, Aadi Bioscience, GlaxoSmithKline, Bayer, Eisai Limited and Others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1621922758.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Osteosarcoma Market Size, Epidemiology, Treatment, Therapies and Companies by DelveInsight | Eleison Pharmaceuticals, Aadi Bioscience, GlaxoSmithKline, Bayer, Eisai Limited and Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1621922758.jpeg\" alt=\"Osteosarcoma Market Size, Epidemiology, Treatment, Therapies and Companies by DelveInsight | Eleison Pharmaceuticals, Aadi Bioscience, GlaxoSmithKline, Bayer, Eisai Limited and Others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Osteosarcoma Market<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s &ldquo;<strong>Osteosarcoma Market<\/strong><strong> Insights, Epidemiology, and Market Forecast-2030<\/strong>&rdquo; report delivers an in-depth understanding of the Osteosarcoma (OS), historical and forecasted epidemiology as well as the&nbsp; Osteosarcoma (OS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the<\/strong> <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/osteosarcoma-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Osteosarcoma Market<\/a><\/strong><strong> Report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The therapeutic market of Osteosarcoma in the 7MM was <strong>USD 72.50 million<\/strong> in 2017.<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li>Osteosarcoma (OS) is a relatively rare tumour of bone with a worldwide Prevalence of 3.4 cases per million people per year.&nbsp;<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li>As per DelveInsight estimates, the Incident cases of Osteosarcoma in the 7MM were&nbsp;<strong>2,228<\/strong>&nbsp;cases in 2020 during the study period (2018&ndash;2030).<\/li>\n<li>The incident cases of Osteosarcoma in the United States was&nbsp;<strong>1,174<\/strong>&nbsp;patients in 2020.<\/li>\n<li>Our Reports estimate that males have higher cases in comparison to females. In 2020, males and females accounted for&nbsp;<strong>620 and 554<\/strong>&nbsp;cases of Osteosarcoma.<\/li>\n<li>Based on the stages of cancer, Osteosarcoma is categorized into localized, regional, and distant stages. Localized and regional are further defined as non-metastatic, whereas, the &lsquo;distant&rsquo; stage is defined as metastasis. The localized and regional stage incident cases accounted for&nbsp;<strong>387 and 563<\/strong>&nbsp;cases in 2020. In the same year, distant staged Osteosarcoma cases contributed to&nbsp;<strong>223&nbsp;<\/strong>cases in the US.<\/li>\n<li>Various companies are developing therapies for the treatment of patients with Osteosarcoma i.e. Lenvatinib (Eisai Limited), Regorafenib (Bayer), Cabozantinib S-malate (Exelixis), Pazopanib Hydrochloride and Topotecan Hydrochloride (GSK), Bempegaldesleukin (NKTR-214) Plus Nivolumab (Nektar therapeutics).<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for sample pages:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/osteosarcoma-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/osteosarcoma-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key benefits of the Osteosarcoma report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Osteosarcoma (OS) market report covers a descriptive overview and comprehensive insight of the Osteosarcoma (OS) epidemiology and Osteosarcoma (OS) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) &amp; Japan.)<\/li>\n<li>The Osteosarcoma (OS) market report provides insights on the current and emerging therapies.<\/li>\n<li>Osteosarcoma (OS) market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/li>\n<li>The Osteosarcoma (OS) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Osteosarcoma (OS) market.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>The key players involved in the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/osteosarcoma-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Osteosarcoma market<\/a>:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Eleison Pharmaceuticals&nbsp;<\/li>\n<li>Aadi Bioscience<\/li>\n<li>GlaxoSmithKline<\/li>\n<li>Bayer<\/li>\n<li>Eisai Limited<\/li>\n<li>Exelixis<\/li>\n<li>Nektar Therapeutics<\/li>\n<li>Cellectar Biosciences<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for sample pages:&nbsp;<\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/osteosarcoma-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/osteosarcoma-market<\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Osteosarcoma Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Osteosarcoma (also called osteogenic sarcoma) is the most common type of cancer that starts in the bones. The cancer cells in these tumors look like early forms of bone cells that normally help make new bone tissue, but the bone tissue in an osteosarcoma is not as strong as that of normal bones.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>The launch of the emerging therapies is expected to significantly impact the&nbsp;Osteosarcoma treatment&nbsp;scenario in the upcoming years:-<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of Osteosarcoma Drug covered<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Inhaled lipid-complexed cisplatin<\/li>\n<li>ABI-009<\/li>\n<li>Lenvatinib<\/li>\n<li>Regorafenib<\/li>\n<li>Cabozantinib S-malate<\/li>\n<li>Pazopanib Hydrochloride and Topotecan Hydrochloride<\/li>\n<li>Bempegaldesleukin (NKTR-214) Plus Nivolumab<\/li>\n<li>CLR 131<\/li>\n<li>And Many Others<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for sample pages:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/osteosarcoma-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/osteosarcoma-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis<\/p>\n<p style=\"text-align: justify;\">4. Osteosarcoma (OS) Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Osteosarcoma (OS) Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Osteosarcoma (OS) Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Osteosarcoma (OS) Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Osteosarcoma (OS)<\/p>\n<p style=\"text-align: justify;\">9. Osteosarcoma (OS) Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Osteosarcoma (OS) Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Osteosarcoma (OS) Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Osteosarcoma (OS) Market Analysis (2017&ndash;2030)<\/p>\n<p style=\"text-align: justify;\">14. Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Market drivers<\/p>\n<p style=\"text-align: justify;\">16. Market barriers<\/p>\n<p style=\"text-align: justify;\">17. Appendix<\/p>\n<p style=\"text-align: justify;\">18. Osteosarcoma (OS) Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Detailed TOC:&nbsp;<\/strong>https:\/\/www.delveinsight.com\/sample-request\/osteosarcoma-market<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;<\/strong><strong>DelveInsight<\/strong><strong><br \/> <\/strong>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=osteosarcoma-market-size-epidemiology-treatment-therapies-and-companies-by-delveinsight-eleison-pharmaceuticals-aadi-bioscience-glaxosmithkline-bayer-eisai-limited-and-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/osteosarcoma-market\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/osteosarcoma-market<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/osteosarcoma-market\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=osteosarcoma-market-size-epidemiology-treatment-therapies-and-companies-by-delveinsight-eleison-pharmaceuticals-aadi-bioscience-glaxosmithkline-bayer-eisai-limited-and-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Osteosarcoma Market DelveInsight&rsquo;s &ldquo;Osteosarcoma Market Insights, Epidemiology, and Market Forecast-2030&rdquo; report delivers an in-depth understanding of the Osteosarcoma (OS), historical and forecasted epidemiology as well as the&nbsp; Osteosarcoma (OS) market trends in the United States, EU5 (Germany, Spain, Italy, France, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/osteosarcoma-market-size-epidemiology-treatment-therapies-and-companies-by-delveinsight-eleison-pharmaceuticals-aadi-bioscience-glaxosmithkline-bayer-eisai-limited-and-others_544622.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-544622","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/544622","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=544622"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/544622\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=544622"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=544622"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=544622"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}